Clinical Trials Logo

Type I Diabetes clinical trials

View clinical trials related to Type I Diabetes.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT02117518 Not yet recruiting - Type I Diabetes Clinical Trials

Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients

Start date: May 2014
Phase: N/A
Study type: Observational

It is well established that CD8 and CD4 T cells reactive against defined islet antigens are associated with initiation and progression of Type 1 Diabetes (T1D). In previous work, we have demonstrated that it is possible to redirect T cells against pathogenic T cells via chimeric peptide/MHC/CD3-zeta receptors in a peptide-specific manner and to prevent, or inhibit diabetes in NOD mice. In this study we intend to extend this approach to T cells of T1D patients. Working hypothesis: Beta cell-reactive CD8 T cells of human T1D patients can be immuno-targeted by their own gene-modified cytotoxic T lymphocytes (CTLs). Aims: Our major aim is to demonstrate, in a set of ex-vivo experiments, such immunotargeting with T cells derived from T1D patients at the Ziv Medical Center. To this end we will stimulate and expand autoreactive CD8 cells in blood samples of T1D patients and target them, ex-vivo, with genetically-reprogrammed CTLs which are present in the same blood samples.